Published in J Bone Miner Res on November 01, 2002
Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc (2008) 2.66
A comparison of parathyroid hormone-related protein (1-36) and parathyroid hormone (1-34) on markers of bone turnover and bone density in postmenopausal women: the PrOP study. J Bone Miner Res (2013) 1.65
Capture the Fracture: a Best Practice Framework and global campaign to break the fragility fracture cycle. Osteoporos Int (2013) 1.60
Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int (2008) 1.50
Effect of dosing interval duration of intermittent ibandronate treatment on the healing process of femoral osteotomy in a rat fracture model. Calcif Tissue Int (2012) 1.41
Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc (2009) 1.39
Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study. J Bone Miner Metab (2005) 1.34
Canadian Consensus Conference on osteoporosis, 2006 update. J Obstet Gynaecol Can (2006) 1.33
Bisphosphonates in the management of postmenopausal osteoporosis--optimizing efficacy in clinical practice. Clin Interv Aging (2008) 1.22
Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag (2010) 1.12
Prevention and treatment of systemic glucocorticoid side effects. Int J Dermatol (2010) 1.07
Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen. J Bone Miner Metab (2006) 1.06
Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature. Clin Interv Aging (2008) 0.96
Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis. Osteoporos Int (2011) 0.91
Progress in osteoporosis and fracture prevention: focus on postmenopausal women. Arthritis Res Ther (2009) 0.85
Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations. MedGenMed (2004) 0.84
Management of age-related osteoporosis and prevention of associated fractures. Ther Clin Risk Manag (2006) 0.83
A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. Osteoporos Int (2005) 0.82
The effects of weekly alendronate therapy in Taiwanese males with osteoporosis. J Bone Miner Metab (2009) 0.80
Monitoring strontium ranelate therapy in patients with osteoporosis. Osteoporos Int (2009) 0.80
The aging spine: new technologies and therapeutics for the osteoporotic spine. Eur Spine J (2003) 0.79
The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis. J Bone Miner Metab (2009) 0.79
Alendronate sodium in the management of osteoporosis. Ther Clin Risk Manag (2006) 0.77
Differences between the bisphosphonates for the prevention and treatment of osteoporosis. Ther Clin Risk Manag (2006) 0.77
Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: review of a novel, easy to swallow formulation. Clin Interv Aging (2013) 0.77
Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis. Ther Clin Risk Manag (2006) 0.77
Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis. Rheumatol Int (2004) 0.77
Evidence of sustained vertebral and nonvertebral antifracture efficacy with ibandronate therapy: a systematic review. Ther Adv Musculoskelet Dis (2011) 0.76
Medical treatment of osteoporotic vertebral fractures. Ther Adv Musculoskelet Dis (2011) 0.76
The therapeutic effectiveness of the coadministration of weekly risedronate and proton pump inhibitor in osteoporosis treatment. J Osteoporos (2014) 0.75
A critical review of brand and generic alendronate for the treatment of osteoporosis. Springerplus (2013) 0.75
Relationship Between Urinary Cross-Linked N-Telopeptide of Type-I Collagen and Heel Stiffness Index Measured by Quantitative Ultrasound in Middle-Aged and Elderly Men. Medicine (Baltimore) (2015) 0.75
Concern Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med (2000) 29.03
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med (2001) 9.57
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet (2013) 8.16
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int (2007) 6.44
Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum (1995) 5.32
The hypocalciuric or benign variant of familial hypercalcemia: clinical and biochemical features in fifteen kindreds. Medicine (Baltimore) (1981) 5.29
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int (2000) 4.85
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int (2008) 4.73
Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med (1998) 4.38
Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab (2005) 3.67
Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int (2010) 3.36
Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med (1993) 3.23
Alendronate for the treatment of osteoporosis in men. N Engl J Med (2000) 3.11
A herpesvirus of rhesus monkeys related to the human Kaposi's sarcoma-associated herpesvirus. J Virol (1997) 3.10
Mutation in the gene encoding the stimulatory G protein of adenylate cyclase in Albright's hereditary osteodystrophy. N Engl J Med (1990) 3.09
Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. American College of Rheumatology. Arthritis Rheum (1995) 3.05
Knee adduction moment, serum hyaluronan level, and disease severity in medial tibiofemoral osteoarthritis. Arthritis Rheum (1998) 2.89
Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis. Osteoporos Int (2012) 2.81
Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. Fracture Intervention Trial Research Group. J Am Geriatr Soc (2000) 2.80
Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int (2006) 2.79
Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med (1990) 2.76
Growth and neurodevelopmental outcome of VLBW infants at 1 year corrected age. Indian Pediatr (2012) 2.64
The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res (2003) 2.50
A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. J Rheumatol (2000) 2.47
Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA (1997) 2.46
Treatment of arthritis with topical capsaicin: a double-blind trial. Clin Ther (1991) 2.44
Serum interferon levels in patients with systemic lupus erythematosus. Arthritis Rheum (1982) 2.40
A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum (2001) 2.37
Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int (2006) 2.34
Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab (2000) 2.34
The transcriptome of the arbuscular mycorrhizal fungus Glomus intraradices (DAOM 197198) reveals functional tradeoffs in an obligate symbiont. New Phytol (2011) 2.29
Evaluation of housestaff physicians' preparation and interpretation of sputum Gram stains for community-acquired pneumonia. J Gen Intern Med (1991) 2.28
Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus. J Virol (1997) 2.27
Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome. Proc Natl Acad Sci U S A (1992) 2.26
Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone (2000) 2.24
The time course of a hypercalcaemic crisis in acute primary hyperparathyroidism. Lancet (1984) 2.21
Primary hyperparathyroidism. Lancet (1997) 2.17
Resistance to multiple hormones in patients with pseudohypoparathyroidism. Association with deficient activity of guanine nucleotide regulatory protein. Am J Med (1983) 2.14
Brain: gadolinium-enhanced fast fluid-attenuated inversion-recovery MR imaging. Radiology (1999) 2.07
Bone marrow and spleen: dissociation of immunologic properties by cortisone. Science (1970) 2.02
Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. Ann Intern Med (1999) 2.01
Definition of bacteriophage groups according to their lytic action on mesophilic lactic streptococci. Appl Environ Microbiol (1976) 1.98
Morphological and biochemical characterization of viral particles produced by the tsO45 mutant of vesicular stomatitis virus at restrictive temperature. J Virol (1979) 1.93
Defining the roles of parathyroid hormone-related protein in normal physiology. Physiol Rev (1996) 1.91
FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun (2001) 1.90
Endoscopic surgery versus medical treatment for spontaneous intracerebral hematoma: a randomized study. J Neurosurg (1989) 1.89
Diabetic muscle infarction. Am J Med (1996) 1.88
The Global Longitudinal Study of Osteoporosis in Women (GLOW): rationale and study design. Osteoporos Int (2009) 1.85
A prospective study of the incidence and nature of injuries to adult rugby players. S Afr Med J (1990) 1.82
Comparison of radiometric and gas capture system for blood cultures. J Clin Pathol (1986) 1.81
Quantitative heel ultrasound in a population-based study in Italy and its relationship with fracture history: the ESOPO study. Osteoporos Int (2005) 1.80
Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res (2000) 1.80
Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. Am J Med (1990) 1.79
Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int (2008) 1.76
Invasive zygomycosis in India: experience in a tertiary care hospital. Postgrad Med J (2009) 1.74
Individual smallest detectable difference in bone mineral density measurements. J Bone Miner Res (1999) 1.74
High prevalence of hypovitaminosis D in female type 2 diabetic population. Diabetes Care (2001) 1.74
Noninfectious vesicular stomatitis virus particles deficient in the viral nucleocapsid. J Virol (1979) 1.72
Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. JAMA (2001) 1.72
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis (2005) 1.66
Knee pain and joint loading in subjects with osteoarthritis of the knee. J Orthop Res (2000) 1.66
Molecular diagnosis of residual and recurrent thyroid cancer by amplification of thyroglobulin messenger ribonucleic acid in peripheral blood. J Clin Endocrinol Metab (1998) 1.65
Validity of the in-training examination for predicting American Board of Internal Medicine certifying examination scores. J Gen Intern Med (1992) 1.65
Developing a Canadian prescribing practices network. Network Development Committee of the Canadian Prescribing Practices Network Project. CMAJ (1996) 1.64
Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int (2004) 1.60
Development after exposure to mifepristone in early pregnancy. Lancet (1991) 1.59
DXA scanning in clinical practice. QJM (2008) 1.59
Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) (2000) 1.59
Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum (2001) 1.58
Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab (2000) 1.58
Primary structure of bovine pituitary secretory protein I (chromogranin A) deduced from the cDNA sequence. Proc Natl Acad Sci U S A (1987) 1.58
Studies on the development of high-protein biscuits from composite flours. Plant Foods Hum Nutr (1993) 1.58
Incidence and costs of hip fractures compared to acute myocardial infarction in the Italian population: a 4-year survey. Osteoporos Int (2006) 1.54
Deficient activity of guanine nucleotide regulatory protein in erythrocytes from patients with pseudohypoparathyroidism. Biochem Biophys Res Commun (1980) 1.54
Mutation of the signal peptide-encoding region of the preproparathyroid hormone gene in familial isolated hypoparathyroidism. J Clin Invest (1990) 1.52
Minor injuries in ninth class school children of Chandigarh and rural Haryana. Indian Pediatr (1996) 1.52
'Senile' osteoporosis reconsidered. JAMA (1989) 1.51
Biomedical information technology: medicine and health care in the digital future. IEEE Trans Inf Technol Biomed (1997) 1.51
Precision of 3.0 Tesla quantitative magnetic resonance imaging of cartilage morphology in a multicentre clinical trial. Ann Rheum Dis (2008) 1.50
An integrated SSR map of grapevine based on five mapping populations. Theor Appl Genet (2006) 1.49
Familial isolated hypoparathyroidism caused by a mutation in the gene for the transcription factor GCMB. J Clin Invest (2001) 1.48
Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus. J Virol (2000) 1.47
Specificity of G protein beta and gamma subunit interactions. J Biol Chem (1992) 1.46
Erythromycin ototoxicity: prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia. Am J Med (1992) 1.46
Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med (1996) 1.46